GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group A/S (OCSE:PEG) » Definitions » Cyclically Adjusted Book per Share

Pharma Equity Group A/S (OCSE:PEG) Cyclically Adjusted Book per Share : kr5.20 (As of Mar. 2024)


View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group A/S Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Pharma Equity Group A/S's adjusted book value per share for the three months ended in Mar. 2024 was kr0.031. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is kr5.20 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Pharma Equity Group A/S's average Cyclically Adjusted Book Growth Rate was -57.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-12), Pharma Equity Group A/S's current stock price is kr0.261. Pharma Equity Group A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was kr5.20. Pharma Equity Group A/S's Cyclically Adjusted PB Ratio of today is 0.05.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Pharma Equity Group A/S was 0.05. The lowest was 0.00. And the median was 0.00.


Pharma Equity Group A/S Cyclically Adjusted Book per Share Historical Data

The historical data trend for Pharma Equity Group A/S's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Equity Group A/S Cyclically Adjusted Book per Share Chart

Pharma Equity Group A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 13.20 12.30 7.03

Pharma Equity Group A/S Quarterly Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.13 10.43 8.96 7.03 5.20

Competitive Comparison of Pharma Equity Group A/S's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Pharma Equity Group A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharma Equity Group A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group A/S's Cyclically Adjusted PB Ratio falls into.



Pharma Equity Group A/S Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Pharma Equity Group A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.031/118.4000*118.4000
=0.031

Current CPI (Mar. 2024) = 118.4000.

Pharma Equity Group A/S Quarterly Data

Book Value per Share CPI Adj_Book
201106 59.251 96.100 73.000
201109 57.244 96.300 70.381
201112 52.569 96.300 64.633
201203 50.628 98.300 60.980
201206 47.303 98.200 57.033
201209 44.420 98.700 53.286
201212 24.011 98.300 28.921
201303 21.168 99.300 25.240
201306 -21.033 99.100 -25.129
201309 -25.422 99.200 -30.342
201312 -69.576 99.000 -83.210
201403 -71.758 99.600 -85.303
201406 -32.356 99.700 -38.425
201409 -32.411 99.700 -38.490
201412 4.494 99.400 5.353
201503 4.474 100.200 5.287
201506 4.441 100.300 5.242
201509 4.403 100.200 5.203
201512 4.366 99.800 5.180
201603 4.349 100.200 5.139
201606 4.340 100.600 5.108
201612 4.338 100.300 5.121
201706 4.334 101.200 5.071
201712 3.595 101.300 4.202
201806 0.860 102.300 0.995
201812 3.257 102.100 3.777
201906 3.128 102.900 3.599
201912 2.111 102.900 2.429
202006 1.736 103.200 1.992
202012 1.077 103.400 1.233
202106 1.056 105.000 1.191
202112 1.141 106.600 1.267
202206 1.189 113.600 1.239
202209 0.000 116.400 0.000
202212 1.235 115.900 1.262
202303 0.060 117.300 0.061
202306 0.055 116.400 0.056
202309 0.050 117.400 0.050
202312 0.038 116.700 0.039
202403 0.031 118.400 0.031

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Pharma Equity Group A/S  (OCSE:PEG) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Pharma Equity Group A/S's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=0.261/5.2
=0.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Pharma Equity Group A/S was 0.05. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Pharma Equity Group A/S Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group A/S's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Pharma Equity Group A/S (OCSE:PEG) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970
Pharma Equity Group A/S is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develops technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement.